GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » Price-to-Owner-Earnings

Fusen Pharmaceutical Co (HKSE:01652) Price-to-Owner-Earnings : (As of Jun. 20, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co Price-to-Owner-Earnings?

As of today (2024-06-20), Fusen Pharmaceutical Co's share price is HK$1.17. Fusen Pharmaceutical Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Fusen Pharmaceutical Co's Price-to-Owner-Earnings or its related term are showing as below:

During the past 9 years, the highest Price-to-Owner-Earnings of Fusen Pharmaceutical Co was 48.79. The lowest was 9.53. And the median was 29.68.


HKSE:01652's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.615
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-20), Fusen Pharmaceutical Co's share price is HK$1.17. Fusen Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.06. Therefore, Fusen Pharmaceutical Co's PE Ratio for today is At Loss.

As of today (2024-06-20), Fusen Pharmaceutical Co's share price is HK$1.17. Fusen Pharmaceutical Co's EPS without NRI for the trailing twelve months (TTM) ended in was HK$-0.03. Therefore, Fusen Pharmaceutical Co's PE Ratio without NRI for today is At Loss.

During the past 9 years, Fusen Pharmaceutical Co's highest PE Ratio without NRI was 118.04. The lowest was 0.00. And the median was 25.87.


Fusen Pharmaceutical Co Price-to-Owner-Earnings Historical Data

The historical data trend for Fusen Pharmaceutical Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co Price-to-Owner-Earnings Chart

Fusen Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only - 42.15 - - -

Fusen Pharmaceutical Co Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fusen Pharmaceutical Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Fusen Pharmaceutical Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusen Pharmaceutical Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fusen Pharmaceutical Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Fusen Pharmaceutical Co's Price-to-Owner-Earnings falls into.



Fusen Pharmaceutical Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Fusen Pharmaceutical Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.17/-0.33
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusen Pharmaceutical Co  (HKSE:01652) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Fusen Pharmaceutical Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusen Pharmaceutical Co (HKSE:01652) Business Description

Traded in Other Exchanges
N/A
Address
Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN
Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicine and which includes oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.
Executives
Cao Changcheng 2201 Interest of corporation controlled by you
Quan Xiufeng 2202 Interest of your spouse
Full Bliss Holdings Limited 2101 Beneficial owner
One Victory Investments Limited 2101 Beneficial owner
Cao Zhiming 2201 Interest of corporation controlled by you
Zhou Peilin 2202 Interest of your spouse
Rayford Global Limited 2306 Nominee for another person
Tct (bvi) Limited 2501 Other
The Core Trust Company Limited 2301 Trustee
First Joint Elegant Limited 2101 Beneficial owner
Fung Wai Sze 2202 Interest of your spouse
Lam Yiu Por 2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co (HKSE:01652) Headlines

No Headlines